An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
- Status
- RECRUITING
- Phase
- PHASE2
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CD8 PET Imaging in Metastatic Solid Tumours
- Status
- RECRUITING
- Phase
- PHASE2
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
- Status
- RECRUITING
- Phase
- NA
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- N/A
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
The Sagittarius Trial
- Status
- RECRUITING
- Phase
- PHASE3
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- N/A
Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
- Status
- TERMINATED
- Phase
- N/A
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
- Status
- WITHDRAWN
- Phase
- PHASE2